In This Episode
Phil and Christy react to the news Biogen is resurrecting aducanumab, the most promising drug in development in years, after failing a futility study in March. We wonder what’s really going on here: is aducanumab the magic bullet or false hope?
In this episode, we discuss:
- The timeline of aducanumab
- Phil’s very personal stake in the news
- Christy recalls when Namenda (memantine), the last FDA-approved dementia medication, hit the market and the effect it had on two of her residents
- The existing four FDA-approved dementia medications
- The impact using dementia medications can have on a person’s quality of life
- A different take on how we measure costs related to dementia
- The amyloid hypothesis and the role of environment and genetics
- The really important thing Phil feels like he got out of the news
- Biogen Trial Participant Seeks to Understand Science Behind Alzheimer’s Drug
- The only four currently approved dementia-specific medications: Aricept (donepezil), Razadyne (galantamine) , Exelon (rivastigmine), and Namenda (memantine)
- PET scan costs
- How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
For Care Partners
Dementia can last 20+ years. That's a long time to struggle with trial and error!
If you're ready to step out of overwhelm (and anxiety about the future), click the button below now to schedule your complimentary Dementia Caregiver Strategy call with Christy. (Mobile users, click HERE.)
It's time for you and your person to step into the life you deserve.
Mike Good founded The Alzheimer’s Podcast in May 2017. Christy appears as a guest in episodes 15, 19, 21, and 23-26. She became the featured expert on the show starting with episode 28 and appears in every episode after, except 56. When Mike decided to follow his bliss, Christy took over the show in January 2019.
If you have questions or comments for Phil (or me), please let us know! We love hearing from you 🙂